Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study

@inproceedings{Kao2018ProstateselectiveA,
  title={Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study},
  author={Wei-Heng Kao and Chang-Fu Kuo and I J Chou and L-C See and Wen-Kuan Huang and Meng-Jiun Chiou and Weiya Zhang and Michael Doherty and Chun-Chieh Wang and Jun-Te Hsu and Hsien-Hsin Chen and Ji-Hong Hong},
  booktitle={Oncotarget},
  year={2018}
}
Introductions Prostate-selective α antagonists are recommended for relief of lower urinary tract symptoms in prostate cancer patients despite uncertainty of fracture risk as an addition to androgen deprivation therapy (ADT). The purpose of this study is to estimate fracture risk associated with these medications in prostate cancer patients who did and did not receive ADT. Methods The Taiwan National Health Insurance database was used to identify prostate cancer patients. We identified all 90… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 1 EXCERPT